Immunotherapy for Infectious Diseases

Immune Reconstitution with Antiretroviral Chemotherapy 177
95. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4� lymphocytes
after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest
1999; 103:1391–1398.
96. Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in
HIV-infected patients. J Clin Invest 1998; 102:79–87.
97. Zhang Z, Notermans DW, Sedgewick G, et al. Kinetics of CD4� T cell repopulation of lymphoid
tissues after treatment of HIV-1 infection. Proc Natl Acad Sci 1998; 95:1154–1159.
98. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T
lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5:83–89.
99. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4� T-cell
phenotype and depletions within the CD4� T-cell repertoire that are not immediately
restored by antiviral or immune-based therapies. Nat Med 1997; 3:533–540.
100. Gorochov G, Neumann AU, Kereveur A, et al. Perturbation of CD4� and CD8� T-cell
repertoires during progression to AIDS and regulation of the CD4� repertoire during
antiviral therapy. Nat Med 1998; 4:215–221.
101. Kostense S, Raaphorst FM, Notermans DW, et al. Diversity of the T-cell receptor BV
repertoire in HIV-1-infected patients reflects the biphasic CD4� T-cell repopulation kinetics
during highly active antiretroviral therapy. AIDS 1998; 12:F235–F240.
102. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in
adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells.
Blood 1997; 90:3789–3798.
103. Bell EB, Sparshott SM. Interconversion of CD45R subsets of CD4 T cells in vivo. Nature
1990; 348:163–166.
104. Walker RE, Carter CS, Muul L, et al. Peripheral expansion of pre-existing T cells is an
important means of CD4� T-cell regeneration in HIV-infected adults. Nat Med 1998;
4:852–856.
105. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and
during the treatment of HIV infection. Nature 1998; 396:690–695.
106. McCune JM, Hanley MB, Cesar D, et al. Factors influencing T-cell turnover in HIV-1seropositive
patients. J Clin Invest 2000; 105:565–616.
107. Hazenberg MD, Otto SA, Cohen Stuart JW, et al. Increased cell division but not thymic
dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell
population in HIV-1 infection. Nature Med 2000; 6:1036–1042.
108. Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful
potent antiretroviral therapy in previously untreated human immunodeficiency
virus type 1-infected adults. J Infect Dis 1999; 180:1050–1056.
109. Valdez H, Connick E, Lederman M, et al. T-lymphocyte changes after 3 years of controlled
viral replication. In: 8th Conference on Retroviruses and Opportunistic Infections,
Chicago, IL, 2001 [Abstract 372].
110. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection
according to immunologic and virologic response after 6 months of highly active antiretroviral
therapy. Ann Intern Med 2000; 133:401–410.
111. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell
dysfunction in asymptomatic human immunodeficiency virus-seropositive patients: independence
of CD4� cell numbers and clinical staging. J Clin Invest 1989; 84:1892–1899.
112. Dolan MJ, Clerici M, Blatt SP, et al. In vitro T cell function, delayed type hypersensitivity
skin testing, and CD4� T cell subset phenotyping independently predict survival time
in patients infected with human immunodeficiency virus. J Infect Dis 1995; 172:79–87.
113. Rinaldo CR Jr, Liebmann JM, Huang XL, et al. Prolonged suppression of human immunodeficiency
virus type 1 (HIV-1) viremia in persons with advanced disease results in
enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
J Infect Dis 1999; 179:329–336.